# Table S1 Search strategy in electronic database.

|  |  |  |
| --- | --- | --- |
| **Database** | **Search terms** | **Results** |
| PubMed | #1 ((((((((((((NSCLC[Title/Abstract]) OR (Carcinoma, Non Small Cell Lung[Title/Abstract])) OR (Carcinomas, Non-Small-Cell Lung[Title/Abstract])) OR (Lung Carcinoma, Non-Small-Cell[Title/Abstract])) OR (Lung Carcinomas, Non-Small-Cell[Title/Abstract])) OR (Non-Small-Cell Lung Carcinomas[Title/Abstract])) OR (Non-Small-Cell Lung Carcinoma[Title/Abstract])) OR (Non Small Cell Lung Carcinoma[Title/Abstract])) OR (Carcinoma, Non-Small Cell Lung[Title/Abstract])) OR (Non-Small Cell Lung Carcinoma[Title/Abstract])) OR (Non-Small Cell Lung Cancer[Title/Abstract])) OR (Nonsmall Cell Lung Cancer[Title/Abstract])) OR (non small cell lung cancer[Title/Abstract]) | 72940 |
| #2 "carcinoma, non small cell lung"[MeSH Terms] | 57218 |
| #3 #1 OR #2 | 83185 |
| #4 (((((((((((((((((((((((((((((((((((((((((immunotherapy[Title/Abstract]) OR (immune checkpoint inhibitor[Title/Abstract])) OR (immune checkpoint blockade[Title/Abstract])) OR (pd-1 inhibitor[Title/Abstract])) OR (pd-l1 inhibitor[Title/Abstract])) OR (programmed death-ligand 1 inhibitor[Title/Abstract])) OR (ctla-4 inhibitor[Title/Abstract])) OR (immune checkpoint inhibition[Title/Abstract])) OR (cytotoxic t-lymphocyte-associated antigen 4[Title/Abstract])) OR (programmed cell death 1 receptor[Title/Abstract])) OR (programmed cell death 1 ligand 1 protein[Title/Abstract])) OR (cytotoxic t-lymphocyte antigen 4[Title/Abstract])) OR (nivolumab[Title/Abstract])) OR (pembrolizumab[Title/Abstract])) OR (tislelizumab[Title/Abstract])) OR (camrelizumab[Title/Abstract])) OR (sintilimab[Title/Abstract])) OR (durvalumab[Title/Abstract])) OR (atezolizumab[Title/Abstract])) OR (ipilimumab[Title/Abstract])) OR (avelumab[Title/Abstract])) OR (toripalimab[Title/Abstract])) OR (tremelimumab[Title/Abstract])) OR (cemiplimab[Title/Abstract])) OR (Opdivo[Title/Abstract])) OR (BMS-936558[Title/Abstract])) OR (Keytruda[Title/Abstract])) OR (lambrolizumab[Title/Abstract])) OR (MK-3475[Title/Abstract])) OR (SHR-1210[Title/Abstract])) OR (IBI308[Title/Abstract])) OR (Imfinzi[Title/Abstract])) OR (MEDI4736[Title/Abstract])) OR (Tecentriq[Title/Abstract])) OR (RG7446[Title/Abstract])) OR (MPDL3280A[Title/Abstract])) OR (Yervoy[Title/Abstract])) OR (MDX010[Title/Abstract])) OR (bavencio[Title/Abstract])) OR (MSB0010682[Title/Abstract])) OR (ticilimumab[Title/Abstract])) OR (CP 675[Title/Abstract]) | 102579 |
| #5 Immune Checkpoint Inhibitors[MeSH Terms] | 1785 |
| #6 #4 OR #5 | 103256 |
| #7 (((((((((((adverse event[Title/Abstract]) OR (drug toxicity[Title/Abstract])) OR (drug-related side effect[Title/Abstract])) OR (adverse drug reaction[Title/Abstract])) OR (drug side effect[Title/Abstract])) OR (irAE[Title/Abstract])) OR (immune related adverse events[Title/Abstract])) OR (AE[Title/Abstract])) OR (TRAE[Title/Abstract])) OR (adverse events[Title/Abstract])) OR (toxicity[Title/Abstract])) OR (toxicities[Title/Abstract]) | 622253 |
| #8 Drug-Related Side Effects and Adverse Reactions[MeSH Terms] | 120857 |
| #9 #7 OR #8 | 725106 |
| #10 (((((((((clinical trial[Title/Abstract]) OR (cohort study[Title/Abstract])) OR (randomized clinical trial[Title/Abstract])) OR (clinical study[Title/Abstract])) OR (prospective study[Title/Abstract])) OR (prospective trial[Title/Abstract])) OR (retrospective study[Title/Abstract])) OR (retrospective trial[Title/Abstract])) OR (random[Title/Abstract])) OR (RCT[Title/Abstract]) | 1037825 |
| #11 #3 AND #6 AND #9 AND #10 | 213 |
| Web of Science | #1 TS=(NSCLC OR 'non small cell lung cancer' OR 'carcinoma, non small cell lung' OR 'carcinomas, non-small-cell lung' OR 'lung carcinoma, non-small-cell' OR 'non-small-cell lung carcinoma' OR 'non small cell lung carcinoma' OR 'carcinoma, non-small cell lung' OR 'non-small cell lung carcinoma' OR 'non-small cell lung cancer' OR 'nonsmall cell lung cancer') | 144,291 |
| #2 TS=(immunotherapy OR 'immune checkpoint inhibitor' OR 'immune checkpoint blockade' OR 'pd-1 inhibitor' OR 'pd-l1 inhibitor' OR 'programmed death-ligand 1 inhibitor' OR 'ctla-4 inhibitor' OR 'immune checkpoint inhibition' OR 'cytotoxic t-lymphocyte-associated antigen 4' OR 'programmed cell death 1 receptor' OR 'programmed cell death 1 ligand 1 protein' OR 'cytotoxic t-lymphocyte antigen 4' OR nivolumab OR pembrolizumab OR tislelizumab OR camrelizumab OR sintilimab OR durvalumab OR atezolizumab OR ipilimumab OR avelumab OR toripalimab OR tremelimumab OR cemiplimab) | 22328 |
| #3 TS=('adverse event' OR 'drug toxicity' OR 'drug-related side effect' OR 'adverse drug reaction' OR 'drug side effect' OR irae OR 'immune related adverse events' OR 'adverse events' OR 'trae' OR ‘toxicity’ OR ‘toxicities) | 1,843,988 |
| #4 TS=('clinical trial' OR 'cohort study' OR 'randomized clinical trial' OR 'clinical study' OR 'prospective study' OR 'prospective trial' OR 'retrospective study' OR 'retrospective trial' OR ‘random’ OR ‘RCT’) | 9,687,978 |
| #5 #1 AND #2 AND #3 AND #4 | 1,493 |
| Embase | #1 'non small cell lung cancer':ti,ab,kw OR 'carcinoma, non small cell lung':ti,ab,kw OR 'carcinomas, non-small-cell lung':ti,ab,kw OR 'lung carcinoma, non-small-cell\*':ti,ab,kw OR 'non-small-cell lung carcinoma\*':ti,ab,kw OR 'non small cell lung carcinoma':ti,ab,kw OR 'carcinoma, non-small cell lung':ti,ab,kw OR 'non-small cell lung carcinoma':ti,ab,kw OR 'non-small cell lung cancer':ti,ab,kw OR 'nonsmall cell lung cancer':ti,ab,kw OR nsclc:ti,ab,kw | 124039 |
| #2 'non small cell lung cancer'/exp | 170889 |
| #3 #1 OR #2 | 186253 |
| #4 immunotherapy\*:ti,ab,kw OR 'immune checkpoint inhibitor\*':ti,ab,kw OR 'immune checkpoint blockade':ti,ab,kw OR 'pd-1 inhibitor':ti,ab,kw OR 'pd-l1 inhibitor':ti,ab,kw OR 'programmed death-ligand 1 inhibitor':ti,ab,kw OR 'ctla-4 inhibitor':ti,ab,kw OR 'immune checkpoint inhibition':ti,ab,kw OR 'cytotoxic t-lymphocyte-associated antigen 4':ti,ab,kw OR 'programmed cell death 1 receptor':ti,ab,kw OR 'programmed cell death 1 ligand 1 protein':ti,ab,kw OR 'cytotoxic t-lymphocyte antigen 4':ti,ab,kw OR nivolumab:ti,ab,kw OR pembrolizumab:ti,ab,kw OR tislelizumab:ti,ab,kw OR camrelizumab:ti,ab,kw OR sintilimab:ti,ab,kw OR durvalumab:ti,ab,kw OR atezolizumab:ti,ab,kw OR ipilimumab:ti,ab,kw OR avelumab:ti,ab,kw OR toripalimab:ti,ab,kw OR tremelimumab:ti,ab,kw OR cemiplimab:ti,ab,kw | 172901 |
| #5 'immune checkpoint inhibitor'/exp | 5547 |
| #6 #4 OR #5 | 173501 |
| #7 ‘adverse event’:ti,ab,kw OR ‘drug toxicity’:ti,ab,kw OR ‘drug-related side effect’:ti,ab,kw OR ‘adverse drug reaction’:ti,ab,kw OR ‘drug side effect’:ti,ab,kw OR irae:ti,ab,kw OR ‘immune related adverse events’:ti,ab,kw OR ‘adverse events’:ti,ab,kw OR ‘trae’:ti,ab,kw OR ‘toxicity’:ti,ab,kw | 871442 |
| #8 'adverse drug reaction'/exp | 568823 |
| #9 #7 OR #8 | 1,322,911 |
| #10 #3 AND #6 AND #9 | 3715 |
| #11 ‘clinical trial’:ti,ab,kw OR ‘cohort study’:ti,ab,kw OR ‘randomized clinical trial’:ti,ab,kw OR ‘clinical study’:ti,ab,kw OR ‘prospective study’:ti,ab,kw OR ‘prospective trial’:ti,ab,kw OR ‘retrospective study’:ti,ab,kw OR ‘retrospective trial’:ti,ab,kw OR ‘random’:ti,ab,kw OR 'rct':ti,ab,kw | 1481446 |
| #12 #10 AND #11 | 719 |
| Cochrane | #1 (non small cell lung cancer):ti,ab,kw OR (carcinoma, non small cell lung):ti,ab,kw OR (carcinomas, non-small-cell lung):ti,ab,kw OR (lung carcinoma, non-small-cell):ti,ab,kw OR (non-small-cell lung carcinoma):ti,ab,kw | 13977 |
| #2 (non small cell lung carcinoma):ti,ab,kw OR (carcinoma, non-small cell lung):ti,ab,kw OR (non-small cell lung carcinoma):ti,ab,kw OR (non-small cell lung cancer):ti,ab,kw OR (nonsmall cell lung cancer):ti,ab,kw OR nsclc:ti,ab,kw | 114525 |
| #3 MeSH descriptor: [Carcinoma, Non-Small-Cell Lung] explode all trees | 4467 |
| #4 #1 OR #2 OR #3 | 14794 |
| #5 immunotherapy:ti,ab,kw OR (immune checkpoint inhibitor):ti,ab,kw OR (immune checkpoint blockade):ti,ab,kw OR (pd-1 inhibitor):ti,ab,kw OR (pd-l1 inhibitor):ti,ab,kw OR (programmed death-ligand 1 inhibitor):ti,ab,kw OR (ctla-4 inhibitor):ti,ab,kw OR (immune checkpoint inhibition):ti,ab,kw OR (cytotoxic t-lymphocyte-associated antigen 4):ti,ab,kw OR (programmed cell death 1 receptor):ti,ab,kw OR (programmed cell death 1 ligand 1 protein):ti,ab,kw OR (cytotoxic t-lymphocyte antigen 4):ti,ab,kw OR nivolumab:ti,ab,kw OR pembrolizumab:ti,ab,kw OR tislelizumab:ti,ab,kw OR camrelizumab:ti,ab,kw OR sintilimab:ti,ab,kw OR durvalumab:ti,ab,kw OR atezolizumab:ti,ab,kw OR ipilimumab:ti,ab,kw OR avelumab:ti,ab,kw OR toripalimab:ti,ab,kw OR tremelimumab:ti,ab,kw OR cemiplimab:ti,ab,kw | 15312 |
| #6 MeSH descriptor: [Immune Checkpoint Inhibitors] explode all trees | 19 |
| #7 #5 OR #6 | 15314 |
| #8 (adverse event):ti,ab,kw OR (drug toxicity):ti,ab,kw OR (drug-related side effect):ti,ab,kw OR (adverse drug reaction):ti,ab,kw OR (drug side effect):ti,ab,kw OR irae:ti,ab,kw OR (immune related adverse events):ti,ab,kw OR (immune-related adverse events):ti,ab,kw OR (adverse events):ti,ab,kw OR TRAE:ti,ab,kw OR toxicity:ti,ab,kw OR toxicities:ti,ab,kw | 237178 |
| #9 MeSH descriptor: [Drug-Related Side Effects and Adverse Reactions] explode all trees | 3170 |
| #10 #8 OR #9 | 238198 |
| #11 (clinical trial):ti,ab,kw OR (cohort study):ti,ab,kw OR (randomized clinical trial):ti,ab,kw OR (clinical study):ti,ab,kw OR (prospective study):ti,ab,kw OR (prospective trial):ti,ab,kw OR (retrospective study):ti,ab,kw OR (retrospective trial):ti,ab,kw OR random:ti,ab,kw OR RCT:ti,ab,kw | 889832 |
| #12 #4 AND #7 AND #10 AND #11 | 709 |

# Table S2 The baseline characteristics of enrolled studies

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **First Author** | **Year** | **Country** | **Study design** | **No.** | **Treatment** | **Type of irAEs** | **Incidence of irAEs (%)** | **Landmark analysis** | **HR (95% CI) for OS** | **HR (95% CI) for PFS** | **ORR for pts with irAEs (n/N)** | **ORR for pts without irAEs (n/N)** |
| Ahn | 2019 | Korea | retrospective | 155 | PD-1 monotherapy | Mixed | 38.1 | 6-week | 0.4 (0.25-0.65) | 0.36 (0.23-0.561) | NA | NA |
|  |  |  |  |  |  | Skin | NA |  | 0.45 (0.26-0.77) | 0.54 (0.34-0.85) | NA | NA |
|  |  |  |  |  |  | Endocrine | NA |  | 0.49 (0.25-0.96) | 0.57 (0.33-1.01) | NA | NA |
|  |  |  |  |  |  | Lung | NA |  | 4.117 (1.42-11.94) | 1.686 (0.618-4.597) | NA | NA |
| Akamatsu | 2020 | Japan | prospective | 106 | ICI monotherapy | Mixed | 29.2 | not mentioned | 0.45 (0.11-1.88) | 0.3 (0.1-0.85) | NA | NA |
| Aso | 2020 | Japan | retrospective | 155 | PD-1 monotherapy | Skin | 33 | 6-week | 0.34 (0.2-0.6) | 0.38 (0.25-0.58) | NA | NA |
| Baldini | 2020 | Italy | prospective | 1959 | Nivolumab | Mixed | 17.5 | not mentioned | 0.6 (0.51-0.71) | 0.69 (0.6-0.79) | 93/342 | 266/1617 |
| Chen | 2021 | China | retrospective | 191 | ICI monotherapy or combined with chemo | Mixed | 36.6 | not mentioned | 0.65 (0.37-1.13) | 0.63 (0.42-0.95) | 26/62 | 23/89 |
| Campredon | 2020 | France | retrospective | 105 | Nivolumab | Endocrine | 14.3 | 3-month | 0.16 (0.02-1.15) | 0.78 (0.35-1.73) | NA | NA |
| Cortellini | 2019 | Italy | retrospective | 559 | PD-1 monotherapy | Mixed | 41.3 | 6-week | 0.53 (0.41-0.69) | 0.57 (0.45-0.72) | 100/215 | 75/292 |
|  |  |  |  |  |  | Skin | 24.2 |  | 0.43 (0.27-0.7) | 0.46 (0.31-0.69) | NA | NA |
|  |  |  |  |  |  | Endocrine | 33.8 |  | 0.55 (0.37-0.83) | 0.63 (0.45-0.89） | NA | NA |
| Cui | 2020 | China | retrospective | 276 | ICI monotherapy or combined with chemo | Lung | 15.2 | 16-week | NA | 0.48 (0.28-0.8) | NA | NA |
| Kim | 2017 | Korea | retrospective | 58 | PD-1 monotherapy | Endocrine | 32.7 | not mentioned | 0.11 (0.01-0.92) | 0.38 (0.17-0.85) | 24/105 | 9/158 |
| Grangeon | 2019 | France | retrospective | 270 | ICI monotherapy or combined with chemo | Mixed | 44 | not mentioned | 0.29 (0.18-0.46) | 0.42 (0.32-0.57) | NA | NA |
|  |  |  |  |  |  | Endocrine | NA |  | 0.46 (0.25-0.86) | 0.56 (0.39-0.85) | NA | NA |
|  |  |  |  |  |  | Lung | NA |  | 1.42 (0.45-4.54) | 1.19 (0.52-2.7) | NA | NA |
| Dupont | 2019 | France | retrospective | 191 | PD-1 monotherapy | Mixed | 30.4 | not mentioned | 0.36 (0.2-0.65) | NA | NA | NA |
| Fujimoto | 2018 | Japan | retrospective | 613 | Nivolumab | Lung | 10 | 2-month | NA | 0.71 (0.52-0.97) | NA | NA |
| Fukihara | 2019 | Japan | retrospective | 170 | PD-1 monotherapy | Lung | 16 | 6-week | 4.94 (2.4-10.19) | 2.65 (1.35-5.23) | NA | NA |
| Haratani | 2018 | Japan | retrospective | 134 | Nivolumab | Mixed | 51 | 9-week | 0.285 (0.102-0.675) | 0.542 (0.295-0.971) | 23/44 | 17/61 |
|  |  |  |  |  |  | Skin | 32 |  | 0.209 (0.049-0.618) | 0.476 (0.232-0.912) | NA | NA |
|  |  |  |  |  |  | Endocrine | 8 |  | 0.504 (0.027-2.629) | 0.237 (0.037-0.842) | NA | NA |
| Isono | 2021 | Japan | retrospective | 180 | ICI monotherapy | Mixed | 47.2 | not mentioned | 0.611 (0.389-0.96) | NA | 33/85 | 15/95 |
| Kobayashi | 2020 | Japan | prospective | 108 | ICI monotherapy or combined with chemo | Mixed | 31.5 | not mentioned | 0.8 (0.39-1.62) | NA | NA | NA |
| Morimoto | 2021 | Japan | retrospective | 70 | ICI combined with chemo | Mixed | 60 | 12-/24-week | 0.66 (0.3-1.44) | 0.53 (0.3-0.93) | 24/42 | 10/28 |
| Naqash | 2020 | US | retrospective | 531 | Nivolumab | Mixed | 33 | not mentioned | 0.62 (0.55-1.03) | 0.69 (0.55-0.87) | 171/425 | 60/425 |
|  |  |  |  |  |  | Skin | NA |  | 0.67 (0.41-1.07) | 0.57 (0.36-0.88) | NA | NA |
|  |  |  |  |  |  | Endocrine | NA |  | 0.79 (0.53-1.19) | 0.98 (0.67-1.42) | NA | NA |
|  |  |  |  |  |  | Lung | NA |  | 1.35 (0.89-2.02) | 1.36 (0.91-2.02) | NA | NA |
| Osorio | 2020 | US | retrospective | 51 | Pembrolizumab | Endocrine | 21 | not mentioned | 0.29 (0.09-0.94) | 0.58 (0.27-1.21) | NA | NA |
| Owen | 2018 | US | retrospective | 91 | ICI monotherapy | Mixed | 30 | 3-month | 0.364 (0.203-0.649) | NA | NA | NA |
|  |  |  |  |  |  | Endocrine | NA |  | 1.74 (0.34-8.15) | NA | NA | NA |
| Park | 2021 | Korea | retrospective | 1181 | PD-1 monotherapy | Mixed | 20.7 | not mentioned | 0.53 (0.33-0.86) | 0.52 (0.32-0.85) | NA | NA |
| Peiró | 2019 | Spain | prospective | 55 | ICI monotherapy or combined with chemo | Endocrine | 14.6 | not mentioned | 0.4 (0.17-0.94) | NA | NA | NA |
| Ricciuti | 2019 | Italy | retrospective | 195 | Nivolumab | Mixed | NA | 6-/12-week | 0.33 (0.23-0.47) | 0.41 (0.3-0.57) | 37/85 | 11/110 |
|  |  |  |  |  |  | Skin | NA |  | 0.8 (0.46-1.39) | 0.57 (0.35-0.95) | NA | NA |
|  |  |  |  |  |  | Endocrine | NA |  | 0.45 (0.28-0.72) | 0.59 (0.4-0.89) | NA | NA |
|  |  |  |  |  |  | Lung cancer | NA |  | 0.46 (0.24-0.89) | 0.56 (0.33-0.96) | NA | NA |
| Rose | 2021 | US | retrospective | 75 | ICI monotherapy | Mixed | 43.6 | 6-week | 0.43 (0.21-0.93) | NA | NA | NA |
| Rubino | 2021 | Italy | retrospective | 92 | ICI monotherapy | Mixed | NA | not mentioned | 0.26 (0.13-0.53) | 0.28 (0.15-0.53) | NA | NA |
|  |  |  |  |  |  | Endocrine | 30.6 |  | 1.11 (0.52-2.38) | 0.96 (0.5-1.83) | NA | NA |
| Sato | 2018 | Japan | prospective | 38 | Nivolumab | Mixed | 28.9 | 60-day | NA | 0.1 (0.02-0.37) | 7/11 | 2/27 |
| Sonehara | 2021 | Japan | retrospective | 80 | ICI monotherapy | Mixed | 31.3 | not mentioned | 0.3 (0.14-0.63) | 0.23 (0.13-0.43) | 12/25 | 3/51 |
| Sugano | 2020 | Japan | retrospective | 130 | ICI monotherapy | Mixed | 30 | not mentioned | NA | NA | 20/39 | 19/91 |
| Teraoka | 2017 | Japan | prospective | 43 | Nivolumab | Mixed | 44.2 | not mentioned | NA | 0.36 (0.15-0.84） | NA | NA |
| Thuillier | 2021 | France | retrospective | 134 | Nivolumab | Endocrine | 29.9 | not mentioned | 0.32 (0.16-0.62) | 0.36 (0.21-0.62) | NA | NA |
| Toi | 2018 | Japan | retrospective | 70 | Nivolumab | Mixed | 40 | not mentioned | NA | 0.43 (0.21-0.83） | 16/28 | 5/42 |
| Zhang | 2021 | US | retrospective | 63 | Pembrolizumab | Mixed | 38.1 | not mentioned | 0.5 (0.17-1.5) | NA | NA | NA |
| Zhou | 2021 | China | retrospective | 191 | PD-1 monotherapy or combined with chemo | Endocrine | 20.9 | not mentioned | 0.334 (0.196-0.571) | 0.433 (0.242-0.774) | NA | NA |
| Schweizer | 2020 | Germany | prospective | 46 | PD-1 monotherapy or combined with chemo | Mixed | 28 | not mentioned | 0.79 (0.16-3.82) | 0.66 (0.17-2.51) | NA | NA |
| Bouhlel | 2020 | France | retrospective | 69 | Nivolumab | Mixed | 44.9 | not mentioned | 0.4 (0.19-0.89) | 0.64 (0.37-1.1) | NA | NA |

Abbreviations: No., number; irAE, immune-related adverse events; HR, hazard ratio; CI, confidence interval; OS, overall survival; PFS, progression-free survival; ICI, immune checkpoint inhibitor; pts, patients; NA, not applicable

# Table S3 Quality assessment of included studies using the Newcastle-Ottawa Scale (NOS) criteria.

|  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Study** | **Year** | **Selection** | | | | **Comparability** | **Outcome** | | | **Total** |
|  |  | Representativeness of exposed cohort | Selection of the non-exposed cohort | Ascertainment of exposure to implants | Demonstration that outcome of interest was not present at start of study | Comparability of cohorts based on the design or analysis | Assessment of outcome | Follow-up long enough for outcomes to occur | Adequacy of follow up of cohorts |  |
| [Ahn](https://pubmed-ncbi-nlm-nih-gov-443.webvpn.cams.cn/?term=Ahn+BC&cauthor_id=30911841) | 2019 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 7 |
| [Akamatsu](https://pubmed-ncbi-nlm-nih-gov-443.webvpn.cams.cn/?term=Akamatsu+H&cauthor_id=32297443) | 2020 | 1 | 1 | 0 | 1 | 2 | 1 | 1 | 1 | 8 |
| Aso | 2020 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 9 |
| Baldini | 2020 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 7 |
| Chen | 2021 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 9 |
| Campredon | 2020 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 6 |
| Cortellini | 2019 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 6 |
| Cui | 2020 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 0 | 8 |
| Kim | 2017 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 0 | 8 |
| [Grangeon](https://pubmed-ncbi-nlm-nih-gov-443.webvpn.cams.cn/?term=Grangeon+M&cauthor_id=30442524) | 2019 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 6 |
| Dupont | 2019 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 7 |
| Fujimoto | 2018 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 6 |
| Fukihara | 2019 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 0 | 8 |
| Haratani | 2018 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 0 | 8 |
| Isono | 2021 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 6 |
| Kobayashi | 2020 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 7 |
| Morimoto | 2021 | 1 | 1 | 1 | 1 | 2 | 1 | 0 | 1 | 8 |
| Naqash | 2020 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 6 |
| Osorio | 2020 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 7 |
| Owen | 2018 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 0 | 8 |
| Park | 2021 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 0 | 8 |
| Peiró | 2019 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 9 |
| Ricciuti | 2019 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 0 | 8 |
| Rose | 2021 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 0 | 9 |
| Rubino | 2021 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 9 |
| Sato | 2018 | 1 | 1 | 1 | 1 | 2 | 1 | 0 | 1 | 8 |
| Sonehara | 2021 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 6 |
| Sugano | 2020 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 7 |
| Teraoka | 2017 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 9 |
| Thuillier | 2021 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 0 | 8 |
| Toi | 2018 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 0 | 8 |
| Zhang | 2021 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 9 |
| Zhou | 2021 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 0 | 8 |
| Schweizer | 2020 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 0 | 8 |
| Bouhlel | 2020 | 1 | 1 | 1 | 1 | 0 | 1 | 1 | 1 | 7 |